Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma.
Adult
Aged
Disease-Free Survival
Female
Humans
Imidazoles
/ pharmacology
Male
Melanoma
/ diagnostic imaging
Middle Aged
Molecular Targeted Therapy
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Staging
Oximes
/ pharmacology
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Pyridones
/ pharmacology
Pyrimidinones
/ pharmacology
Treatment Outcome
BRAF-targeted therapy
melanoma
neoadjuvant therapy
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
25
05
2019
revised:
02
07
2019
accepted:
04
07
2019
pubmed:
23
7
2019
medline:
11
11
2020
entrez:
23
7
2019
Statut:
ppublish
Résumé
Current management of locoregional and oligometastatic melanoma is typically with surgery; however, some patients are unable to undergo resection due to location/size of their tumors and/or the anticipated morbidity of the surgery. While there are currently no established guidelines for neoadjuvant therapy in melanoma, neoadjuvant BRAF-targeted therapy may make resection more feasible. A retrospective analysis was conducted of 23 patients with BRAFV600-mutant, stage III/IV melanoma treated with BRAF-targeted therapy prior to surgery, with no adjuvant treatment. Surgical specimens, preoperative imaging, and clinical outcomes were evaluated. Results: Ten of 23 patients (44%) attained a pathologic complete response (pCR), with no correlation between RECIST response based on preoperative imaging and pathologic response. After a median of 43-month follow-up, only 1 patient (10%) with a pCR recurred, while 8 of 13 (62%) patients without a pCR recurred. Patients with a pCR had significantly improved relapse-free (RFS) and overall survival (OS) compared to patients with residual tumor. Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS.
Identifiants
pubmed: 31329344
doi: 10.1111/pcmr.12813
pmc: PMC6928428
mid: NIHMS1042782
doi:
Substances chimiques
Imidazoles
0
Oximes
0
Pyridones
0
Pyrimidinones
0
trametinib
33E86K87QN
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
dabrafenib
QGP4HA4G1B
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-95Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA168536
Pays : United States
Organisme : NCI NIH HHS
ID : P30-CA076292
Pays : United States
Organisme : NCI NIH HHS
ID : Skin SPORE P50CA168536-01A1
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ann Oncol. 2018 Aug 1;29(8):1861-1868
pubmed: 29945191
J Am Acad Dermatol. 2014 Feb;70(2):e39-41
pubmed: 24438978
Melanoma Res. 2014 Aug;24(4):413-4
pubmed: 24992629
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Melanoma Res. 2016 Feb;26(1):83-7
pubmed: 26731560
Immunotherapy. 2012 Jul;4(7):679-86
pubmed: 22853754
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Melanoma Res. 2015 Apr;25(2):180-3
pubmed: 25643238
Case Rep Oncol Med. 2013;2013:794239
pubmed: 24455362
J Clin Oncol. 2006 Jul 1;24(19):3157-63
pubmed: 16809738
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
J Clin Oncol. 2013 Jun 1;31(16):e251-3
pubmed: 23569313
Lancet Oncol. 2018 Feb;19(2):181-193
pubmed: 29361468
J Exp Clin Cancer Res. 2000 Mar;19(1):21-34
pubmed: 10840932
J Clin Oncol. 2006 Jul 1;24(19):3164-71
pubmed: 16809739
PLoS One. 2014 Feb 03;9(2):e87705
pubmed: 24498358
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Lancet Oncol. 2018 Feb;19(2):151-153
pubmed: 29361473
Melanoma Res. 1998 Dec;8(6):549-56
pubmed: 9918417
Lancet Oncol. 2019 Jul;20(7):961-971
pubmed: 31171444
J Clin Oncol. 2005 Nov 1;23(31):8057-64
pubmed: 16258104
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
BMJ Case Rep. 2012 Oct 22;2012:
pubmed: 23093505
J Surg Oncol. 2017 Dec;116(7):856-861
pubmed: 28650570
Nat Med. 2021 Feb;27(2):301-309
pubmed: 33558722
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Cancer. 2002 Jan 15;94(2):470-6
pubmed: 11900232